Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

US11932693B2 · kind B2 · utility

Assignees

• BIONTECH SE · DE
• GENMAB A/S · DK

Inventors

• Ugur Sahin · Mainz, DE
• Sina Fellermeier-Kopf · Mainz, DE
• Friederike Gieseke · Mainz, DE
• Karsten BECKMANN · Albany, US
• Claudia PAULMANN · Mainz, DE
• Alexander Muik · Seeheim-Jugenheim, DE
• Ivan KUZMANOV · Mainz, DE
• Esther BREIJ · Utrecht, NL
• Patricia GARRIDO CASTRO · Utrecht, NL
• Jordan BLUM · Utrecht, NL
• Lars Guelen · Utrecht, NL
• Joost J. NEIJSSEN · Werkhoven, NL
• Bart-Jan DE KREUK · Utrecht, NL
• Richard HIBBERT · Utrecht, NL
• Janine Schuurman · Utrecht, NL
• Aran Frank Labrijn · Amsterdam, NL

Key dates

• Filing date: May 11, 2023
• Grant date: Mar 19, 2024
• Expiry date: May 11, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.